0001178913-13-003750.txt : 20131230 0001178913-13-003750.hdr.sgml : 20131230 20131230070215 ACCESSION NUMBER: 0001178913-13-003750 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20131230 FILED AS OF DATE: 20131230 DATE AS OF CHANGE: 20131230 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BioLineRx Ltd. CENTRAL INDEX KEY: 0001498403 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35223 FILM NUMBER: 131301474 BUSINESS ADDRESS: STREET 1: P.O. BOX 45158 STREET 2: 19 HARTUM STREET CITY: JERUSALEM STATE: L3 ZIP: 91450 BUSINESS PHONE: 972-2-548-9100 MAIL ADDRESS: STREET 1: P.O. BOX 45158 STREET 2: 19 HARTUM STREET CITY: JERUSALEM STATE: L3 ZIP: 91450 FORMER COMPANY: FORMER CONFORMED NAME: BioLineRX, Ltd. DATE OF NAME CHANGE: 20100805 6-K 1 zk1314147.htm 6-K zk1314147.htm
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934

For the month of December 2013
_______________________

BioLineRx Ltd.
(Translation of Registrant’s name into English)
_______________________

P.O. Box 45158
19 Hartum Street
Jerusalem 9777518, Israel
(Address of Principal Executive Offices)
_______________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F þ    Form 40-F o

Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934:

Yes o    No þ

 
 
 
 
On December 30, 2013, the Registrant announced that it has engaged the services of Arnon Aharon, M.D. as its new Vice President of Medical Affairs, commencing January 1, 2014. Prior to joining the Registrant, Dr. Aharon served as Clinical Director, Medical Director or VP of Development at several biotechnology companies, the most recent being Thrombotech Ltd. and LycoRed Ltd. In addition, Dr. Aharon has been a partner in R&D Integrative Solutions, a firm that provides consulting services to the biotechnology industry and academic centers. Dr. Aharon holds a B.Sc in Medical Sciences and an M.D. from Tel Aviv University.

Dr. Aharon will be replacing Prof. Moshe Phillip who has served as the Registrant’s Vice President of Medical Affairs and Senior Clinical Advisor since 2004. Prof. Phillip will continue to be the Chairman of the Company’s Scientific Advisory Board and will provide additional services to the Registrant as a consultant.
 
This report on Form 6-K is being incorporated by reference into all effective registration statements filed by the Registrant under the Securities Act of 1933.

 
 
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 
BioLineRx Ltd.
 
  
  By:
/s/ Philip Serlin
  
   
Philip Serlin
  
   
Chief Financial and Operating Officer
  

Dated: December 30, 2013